TerminatedPhase 2

Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration

Stopped: See termination reason in detailed description.

United States10 participantsStarted 2012-08

Plain-language summary

The purpose of this study is to determine the efficacy, safety and tolerability of multiple doses of RN6G in subjects with Geographic Atrophy Secondary to Age-related Macular Degeneration.

Who can participate

Age range60 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Men and women between the ages of 60 and 90 years. * Diagnosis of a geographic atrophy (GA) secondary to dry Age-Related Macular Degeneration. * Best Corrected Visual Acuity (BCVA) of 20/80 or better in the study eye Exclusion Criteria: * Evidence of ocular disease other than geographic atrophy (GA) secondary to dry Age-Related Macular Degeneration in the study eye. * History or diagnosis of exudative (wet) Age-Related Macular Degeneration, with subretinal or choroidal neovascular lesions in the study eye. * Presence of disease or condition that might compromise the cardiovascular, hematological, renal, hepatic, pulmonary, endocrine, central nervous, immune, or gastrointestinal system

What they're measuring

Mean Reduction (in Study Eye) in Rate of Growth of Geographic Atrophy (GA) at Day 309

Timeframe: Baseline and Day 309

Mean Reduction (in Study Eye) in Rate of Growth of GA at Day 449 (End of Study)

Timeframe: Baseline and Day 449

Trial details

NCT IDNCT01577381

SponsorPfizer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2013-09

Results submitted2015-12-09

View on ClinicalTrials.gov More Age-Related Maculopathy trials